MicroSalt's momentum highlights value in Tekcapital

Aim-traded MicroSalt (SALT:77.5p), a company commercialising a patented technology that produces full-flavour low-sodium salt to reduce excess sodium consumption, a significant cause of hypertension and heart disease, has announced a raft of contract wins as I predicted (‘MicroSalt set to announce major contract awards’, 27 September 2024).

Firstly, one of the world's largest food, soft drink and snack manufacturers has placed an initial purchase order for 50,000 lbs of MicroSalt for use in one of its leading food product lines. The customer anticipates additional purchase orders in two more product lines, including a globally distributed cereal and energy bars brand in the first quarter of 2025. Annualised projections discussed with the customer exceed 200,000 lbs.